On October 29, 2025, Galmed Pharmaceuticals Ltd. held its Annual General Meeting where shareholders approved all proposed items outlined in the proxy statement dated September 19, 2025. This filing is significant from an equity investor perspective as it indicates strong shareholder support for the company’s direction.